Download Full Text (269 KB)
Children who have been infected with Respiratory Syncytial Virus have a higher incidence of wheeze-associated clinic visits and hospitalizations compared to children without previous RSV exposure. The purpose of this study is to determine if palivizumab, an immunoglobulin injection used to prevent RSV infections, can decrease the incidence of recurrent wheezing in children. The review of literature will follow male and female children from infancy to age 13 who were treated with palivizumab and compare these children to patients with similar demographics that were not treated with palivizumab to determine if there is any difference in incidence of wheezing. The anticipated results are that patients treated with palivizumab will have a decreased incidence of recurrent wheeze. The findings may indicate that prevention of RSV with palivizumab will improve long-term health in children.
Physician Assistant Studies
Master of Physician Assistant Studies (MPAS)
Antibodies, Monoclonal -- therapeutic use; Bronchiolitis, Viral -- prevention & control; Child; Infant; Palivizumab -- therapeutic use; Respiratory Sounds; Respiratory Syncytial Virus Infections -- complications
Medical Immunology | Respiratory Tract Diseases
Daniels, Shelly, "Palivizumab Administration Decreases Recurrent Wheeze" (2014). Physician Assistant Scholarly Project Posters. 114.